The productivity limit of manufacturing blood cell therapy in scalable stirred bioreactors
Manufacture of red blood cells (RBCs) from progenitors has been proposed as a method to reduce reliance on donors. Such a process would need to be extremely efficient for economic viability given a relatively low value product and high 2E12 cell dose. Therefore, the aim of these studies was to defin...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Default Article |
| Published: |
2017
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/2134/23011 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|